Is Immunocore Holdings (IMCR) Undervalued As Its First Type 1 Diabetes Trial Begins?

Immunocore Holdings (IMCR) has just dosed the first type 1 diabetes patient in its Phase 1 trial for IMC-S118AI, a milestone that brings its autoimmune ambitions into clearer focus for investors.

IMCR’s recent Phase 1 progress in type 1 diabetes comes at a time when momentum has been mixed, with a 1-day share price return of 2.17% and a 30-day share price return of 4.04%. However, the year-to-date share price return is down 5.39% and the 3-year total shareholder return is down 28.02%, which suggests that investors are still weighing long-term execution risk against fresh trial milestones.

Scan beyond Immunocore Holdings and line up other potential autoimmune and biotech breakouts using our curated list of 21 high quality undiscovered gems to see what else is moving under the radar.

After a modest bounce and a longer stretch of disappointment, Immunocore Holdings now sits in a kind of valuation limbo. Are investors still being paid for the risk, or has most of the upside already been priced in?

Most Popular Narrative: 49% Undervalued

On the most followed view of Immunocore Holdings, a fair value of $62.50 sits well above the last close at $31.96. That gap puts the spotlight on whether KIMMTRAK, the late stage melanoma pipeline and newer autoimmune efforts can justify such a spread.

Momentum in pipeline diversification, progressing late-stage trials in cutaneous melanoma (TEBE-AM, PRISM-MEL) and expanding into infectious and autoimmune diseases, reduces single-product risk and sets the stage for multiple future revenue streams and earnings expansion.

See why 10 investors see Immunocore Holdings as 49% undervalued.

Result: Fair Value of $62.50 (UNDERVALUED)

Still, the Immunocore Holdings story can change quickly if KIMMTRAK momentum slows before new indications contribute, or if key Phase 3 melanoma trials disappoint.

Find out about the key risks to this Immunocore Holdings narrative.

Next Steps

Mixed sentiment around Immunocore Holdings is clear, and the push now is on you to move fast and stress test the upside and downside yourself. To see what is driving optimism on the reward side, review the 3 key rewards.

Looking for more investment ideas beyond Immunocore Holdings?

If Immunocore Holdings has sharpened your interest, do not stop here. Broaden your watchlist and let data rich screens point you toward fresh opportunities.

• Target resilient balance sheets and steady fundamentals by scanning the list of solid balance sheet and fundamentals (24 results) that investors often overlook until momentum shows up in the price.
• Zero in on quality at a price that still looks reasonable using the 29 high quality undervalued stocks before attention shifts and potential mispricing closes.
• Hunt for ideas with attractive yields and staying power through the 5 dividend fortresses while income opportunities are still hiding in plain sight.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com